{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:04:14Z","timestamp":1760144654891,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This observational, descriptive, longitudinal, and prospective basket-type study (Registry #5289) prospectively evaluated the feasibility and acute toxicity of hypo-fractionated radiotherapy on the first 0.35T MR-LINAC in Spain. A total of 37 patients were included between August and December 2023, primarily with prostate tumors (59.46%), followed by pancreatic tumors (32.44%). Treatment regimens typically involved extreme hypo-fractionated radiotherapy, with precise dose delivery verified through quality assurance measures. Acute toxicity assessment at treatment completion revealed manageable cystitis, with one case persisting at the three-month follow-up. Gastrointestinal toxicity was minimal. For pancreatic tumors, daily adaptation of organ-at-risk (OAR) and gross tumor volume (GTV) was practiced, with median doses to OAR within acceptable limits. Three patients experienced gastrointestinal toxicity, mainly nausea. Overall, the study demonstrates the feasibility and safety of extreme hypo-fractionated radiotherapy on a 0.35T MR-LINAC, especially for challenging anatomical sites like prostate and pancreatic tumors. These findings support the feasibility of MR-LINAC-based radiotherapy in delivering precise treatments with minimal toxicity, highlighting its potential for optimizing cancer treatment strategies.<\/jats:p>","DOI":"10.3390\/cancers16091685","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T08:18:27Z","timestamp":1714119507000},"page":"1685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility and Acute Toxicity of Hypo-Fractionated Radiotherapy on 0.35T MR-LINAC: The First Prospective Study in Spain"],"prefix":"10.3390","volume":"16","author":[{"given":"Daniela","family":"Gonsalves","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"},{"name":"Facultad de Medicina Salud y Deporte, Universidad Europea de Madrid, 28670 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-8197","authenticated-orcid":false,"given":"Abrahams","family":"Ocanto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Meilan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisselott","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-3521","authenticated-orcid":false,"given":"Castalia Fern\u00e1ndez","family":"Pascual","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Teja","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Montijano","family":"Linde","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Guijarro","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rivas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare M\u00e1laga, 29018 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Begara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare M\u00e1laga, 29018 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare Sevilla, 41092 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Andreescu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare Cordoba, 14012 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Holgado","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Alcaraz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Escarlata","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, GenesisCare M\u00e1laga, 29018 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Dzhugashvli","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-0507","authenticated-orcid":false,"given":"Fernando","family":"Lopez-Campos","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-8628","authenticated-orcid":false,"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[{"name":"Advanced Radiation Oncology Department, Cancer Care Center, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Verona, Italy"},{"name":"Radiation Oncology School, University of Brescia, 25121 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-0234","authenticated-orcid":false,"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"},{"name":"Facultad de Medicina Salud y Deporte, Universidad Europea de Madrid, 28670 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/0284186X.2021.2012593","article-title":"Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac","volume":"61","author":"Daamen","year":"2022","journal-title":"Acta Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wegener, D., Thome, A., Paulsen, F., Gani, C., Boldt, J., Butzer, S., Thorwarth, D., Moennich, D., Nachbar, M., and M\u00fcller, A.-C. (2022). First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164651"},{"key":"ref_3","first-page":"100564","article-title":"Adaptive radiotherapy for breast cancer","volume":"39","author":"Kirby","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ocanto, A., Torres, L., Montijano, M., Rinc\u00f3n, D., Fern\u00e1ndez, C., Sevilla, B., Gonsalves, D., Teja, M., Guijarro, M., and Glar\u00eda, L. (2024). MR-LINAC, a New Partner in Radiation Oncology: Current Landscape. Cancers, 16.","DOI":"10.3390\/cancers16020270"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Expert Panel on MR Safety, Kanal, E., Barkovich, A.J., Bell, C., Borgstede, J.P., Bradley, W.G., Froelich, J.W., Gimbel, J.R., Gosbee, J.W., and Kuhni-Kaminski, E. (2013). ACR guidance document on MR safe practices: 2013. J. Magn. Reson. Imaging, 37, 501\u2013530.","DOI":"10.1002\/jmri.24011"},{"key":"ref_8","first-page":"98","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e13523","DOI":"10.1002\/acm2.13523","article-title":"Quality assurance for on-table adaptive magnetic resonance guided radiation therapy: A software tool to complement secondary dose calculation and failure modes discovered in clinical routine","volume":"23","author":"Rippke","year":"2022","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100953","DOI":"10.1016\/j.adro.2022.100953","article-title":"Implementing Magnetic Resonance Imaning-Guided Radiation Therapy in Routine Care: Opportunities and Challenges in the United States","volume":"7","author":"Hehakaya","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_11","first-page":"161","article-title":"Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States\u2014Understanding the transition to adaptive, ultra-hypofractionated treatments","volume":"38","author":"Chuong","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13014-022-02114-2","article-title":"Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia","volume":"17","author":"Slotman","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.clon.2018.08.010","article-title":"Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-Year Clinical Experience","volume":"30","author":"Henke","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1016\/j.prro.2022.09.007","article-title":"Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study\u2014An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy","volume":"13","author":"Teunissen","year":"2023","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5\u2009T MR-guided and daily adapted SBRT for prostate cancer: Feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2017.05.013","article-title":"An evaluation of motion mitigation techniques for pancreatic SBRT","volume":"124","author":"Campbell","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehre","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100506","DOI":"10.1016\/j.adro.2020.06.010","article-title":"Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation","volume":"6","author":"Hassanzadeh","year":"2020","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med."},{"key":"ref_21","first-page":"100738","article-title":"Stereotactic body radiotherapy for pancreatic cancer\u2014A systematic review of prospective data","volume":"45","author":"Shouman","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_22","unstructured":"Real Decreto 1566\/1998 (2024, March 03). Criterios de Calidad de Radioterapia. BOE Numer 206. Available online: https:\/\/www.boe.es\/eli\/es\/rd\/1998\/07\/17\/1566."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_24","first-page":"e1618","article-title":"Online Adaptive Radiation Therapy: Implementation of a New Process of Care","volume":"9","author":"Lamb","year":"2017","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pham, J., Savjani, R.R., Gao, Y., Cao, M., Hu, P., Sheng, K., Low, D.A., Steinberg, M., Kishan, A.U., and Yang, Y. (2021). Evaluation of T2-Weighted MRI for Visualization and Sparing of Urethra with MR-Guided Radiation Therapy (MRgRT) On-Board MRI. Cancers, 13.","DOI":"10.3390\/cancers13143564"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Grimbergen, G., Eijkelenkamp, H., Heerkens, H.D., Raaymakers, B.W., Intven, M.P.W., and Meijer, G.J. (2022). Dosimetric impact of intrafraction motion under abdominal compression during MR-guided SBRT for (Peri-) pancreatic tumors. Phys. Med. Biol., 67.","DOI":"10.1088\/1361-6560\/ac8ddd"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100239","DOI":"10.1016\/j.tipsro.2024.100239","article-title":"Evaluation of clinical parallel workflow in online adaptive MR-guided Radiotherapy: A detailed assessment of treatment session times","volume":"29","author":"Votta","year":"2024","journal-title":"Tech. Innov. Patient Support Radiat. Oncol."},{"key":"ref_29","first-page":"100200","article-title":"Interobserver variation of clinical oncologists compared to therapeutic radiographers (RTT) prostate contours on T2 weighted MRI","volume":"25","author":"Dunlop","year":"2022","journal-title":"Tech. Innov. Patient Support Radiat. Oncol."},{"key":"ref_30","unstructured":"National Comprehensive Cancer Network (2024, January 15). Prostate Cancer (Version 4.2023). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomized, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.adro.2019.07.007","article-title":"A Phase I\/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis","volume":"4","author":"Callan","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13014-022-02047-w","article-title":"Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): A prospective, multicentric phase-II-trial","volume":"17","author":"Ristau","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","article-title":"SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal Irradiation","volume":"104","author":"Alayed","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2018.06.027","article-title":"Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group","volume":"129","author":"Lieng","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)","volume":"80","author":"Valle","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cuccia, F., Corradini, S., Mazzola, R., Spiazzi, L., Rigo, M., Bon\u00f9, M.L., Ruggieri, R., Buglione di Monale, E., Bastia, M., and Magrini, S.M. (2021). MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13081791"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Michalet, M., Riou, O., Cottet-Moine, J., Castan, F., Gourgou, S., Valdenaire, S., Debuire, P., Ailleres, N., Draghici, R., and Charissoux, M. (2022). Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study. Cancers, 14.","DOI":"10.3390\/cancers14081943"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1748-717X-7-74","article-title":"Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas","volume":"7","author":"Lominska","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_42","first-page":"343","article-title":"Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: Experience from two institutions","volume":"4","author":"Wild","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijrobp.2005.07.002","article-title":"Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer","volume":"63","author":"Koong","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bryant, J.M., Mittauer, K.E., Kotecha, R., Contreras, J., Alvarez, D., Kalman, N.S., Hall, M.D., Luciani, G., Romaguera, T., and Mishra, V. (2020). Favorable Initial Outcomes of Abdominopelvic Reirradiation Using Dose-Escalated Magnetic Resonance Image-Guided Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys., 108.","DOI":"10.1016\/j.ijrobp.2020.07.1378"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:00Z","timestamp":1760106840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16091685"],"URL":"https:\/\/doi.org\/10.3390\/cancers16091685","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}